Dernières nouvelles pour Axogen (NASDAQ:AXGN) Stock

Axogen

AXOGEN INC

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Axogen Inc

AxoGen Non-GAAP EPS of $0.05 beats by $0.09, revenue of $47.91M beats by $4.58M

Axogen appoints Michael Dale as CEO

AxoGen (AXGN) has issued an update. Axogen Inc. has updated its corporate presentation, which is now available on its website for analysts, investo...

AxoGen Updates Corporate Presentation for Stakeholders

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Axogen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/axgn-stock-quote/"><strong>AXGN</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Axogen reported earnings per share of 5 cents. This was above the analyst estimate for EPS of -4 cents.</li><li>The company reported revenue of $47.91 million.</li><li>This was 10.42% better than the analyst estimate for revenue of $43.39 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/axgn-stock-earnings-axogen-for-q2-of-2024/">AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q2 2024

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

David Turkaly, an analyst from JMP Securities, reiterated the Buy rating on AxoGen (AXGN – Research Report). The associated price target is $20.00....

Buy Rating Affirmed for AxoGen: Strong Q2 Performance and Strategic Leadership Amidst Market Growth Potential

AxoGen (AXGN) has issued an announcement. The Company has energized its leadership team with the appointment of Mr. Dale as the new CEO and Mr. Tho...

AxoGen Appoints New CEO and Board Chair for Strategic Renewal

Axogen completes marketing submission for Avance Nerve Graft

AxoGen ( ($AXGN) ) just unveiled an update. Axogen Inc., a leader in nerve repair solutions, has announced the completion of its BLA submission to ...

AxoGen Seeks Accelerated FDA Review for Avance Nerve Graft®

AxoGen: An Intriguing Growth Story

AXGN

Press Releases

Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®

News

Health Care

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

General

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Earnings

Axogen, Inc. Reports Second Quarter 2024 Financial Results

Management

Axogen, Inc. Announces New Leadership Appointments

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Comments

Axogen

Actualités

Dernières nouvelles pour Axogen (NASDAQ:AXGN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL